PMC

Consort diagram of study design, accrual and eligibility for Southwest Oncology Group trial SWOG-8814 (The Breast Cancer Intergroup of North America 0100). The figure shows the number randomized, the number who were fully eligible (and analyzed), and the number who actually received their assigned treatment.

Southwest Oncology Group trial SWOG-8814 (North American Breast Intergroup 0100) forest plots of hazard ratios and 95% confidence intervals for major subsets for disease-free survival. Panel A describes the disease-free survival advantage for chemotherapy by possible subsets unadjusted for other covariates. Panel B shows the benefit of CAF-T over CAFT in each subset. The dashed vertical line represents the overall unadjusted hazard ratio in each plot.

Southwest Oncology Group trial SWOG-8814 (North American Breast Intergroup 0100) Kaplan-Meier disease-free survival and overall survival distributions for 566 patients on CAF-T, 550 on CAFT, and 361 on tamoxifen alone. Panel A describes the disease-free survival advantage for the sequential approach, log-rank P=0.002 stratified by number of positive nodes, hormone receptor status, and time of surgery, and Panel B shows superior overall survival the CAF-T group, stratified log-rank P=0.074. Ten-year survival estimates and hazard ratios adjusted for prognostic covariates with 95% confidence intervals are also given.

Southwest Oncology Group trial SWOG-8814 (The Breast Cancer Intergroup of North America 0100) Kaplan-Meier disease-free survival and overall survival distributions for 1116 eligible patients at risk on the combined CAF plus tamoxifen groups (566, CAF-T; 550, CAFT) and 361 on tamoxifen alone. Panel A shows the disease-free survival for the combined CAF plus tamoxifen groups versus tamoxifen alone, log-rank P=0.002, stratified by number of positive nodes, hormone receptor status, and time from definitive surgery.. Panel B depicts the overall survival for the CAF plus tamoxifen versus tamoxifen comparison, stratified log-rank P=0.043. Panel C represents the disease-free survival for the CAFT versus CAF-T comparison, stratified log-rank P=0.055. Panel D shows the overall survival with 10-year estimates for the CAFT versus CAF-T comparison, stratified log-rank P=0.27. Ten-year survival estimates with 95% confidence intervals are also given.